BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 27,000 Shares of Company Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 27,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $92.31, for a total value of $2,492,370.00. Following the completion of the transaction, the chief executive officer owned 36,209 shares of the company’s stock, valued at approximately $3,342,452.79. The trade was a 42.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, October 9th, Ugur Sahin sold 36,209 shares of BioNTech stock. The stock was sold at an average price of $95.37, for a total value of $3,453,252.33.
• On Wednesday, October 7th, Ugur Sahin sold 24,000 shares of BioNTech stock. The stock was sold at an average price of $95.86, for a total value of $2,300,640.00.
• On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The shares were sold at an average price of $96.81, for a total value of $2,033,010.00.
• On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The stock was sold at an average price of $97.23, for a total transaction of $7,000,560.00.
• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The stock was sold at an average price of $97.46, for a total transaction of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $96.96 on Friday. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The company has a 50 day simple moving average of $99.17 and a two-hundred day simple moving average of $95.17. The company has a market capitalization of $24.52 billion, a price-to-earnings ratio of -12.38 and a beta of 1.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The company had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. During the same period in the prior year, the firm earned ($1.60) earnings per share. The business’s revenue for the quarter was down 59.5% compared to the same quarter last year. Analysts expect that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. UBS Group reiterated a “buy” rating on shares of BioNTech in a research note on Wednesday, September 16th. BMO Capital Markets lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $128.00 to $105.00 in a research note on Tuesday, September 8th. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Berenberg Bank set a $140.00 target price on shares of BioNTech in a research note on Wednesday, September 16th. Finally, Argus assumed coverage on shares of BioNTech in a report on Thursday. They set a “hold” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $125.69.

BioNTech News Summary

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Biotech-sector momentum offered a modest tailwind after Moderna’s inclusion in the Nasdaq-100 triggered a sharp move in its shares, while BioNTech also traded higher alongside other major vaccine companies. Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
• Neutral Sentiment: Argus initiated coverage with a Hold rating, adding a cautious view but no immediate change to the company’s fundamentals. Argus coverage reference
• Neutral Sentiment: A report stating that short interest totaled zero shares implies no measurable short-squeeze pressure. The figure may reflect a reporting or data issue and should be interpreted cautiously.
• Negative Sentiment: CEO Ugur Sahin sold 36,209 shares for approximately $3.45 million on October 9 and another 27,000 shares for about $2.49 million on October 8. The transactions were executed under a pre-arranged Rule 10b5-1 plan, which reduces their significance as discretionary signals, but the sales substantially reduced his direct ownership. BioNTech CEO SEC filing
• Negative Sentiment: The latest quarterly results showed continuing commercial pressure: revenue fell 59.5% year over year to $122.31 million, below the $180.18 million consensus estimate, while the company reported a loss of $2.53 per share. Analysts expect a full-year loss, underscoring the need for BioNTech’s pipeline to offset declining COVID-19 vaccine revenue.

Institutional Trading of BioNTech

A number of large investors have recently made changes to their positions in BNTX. Integrated Wealth Concepts LLC purchased a new position in shares of BioNTech during the second quarter valued at approximately $39,000. Farther Finance Advisors LLC boosted its holdings in BioNTech by 31.5% in the third quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after purchasing an additional 118 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in BioNTech by 1,012.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after purchasing an additional 506 shares during the last quarter. Vestcor Inc bought a new stake in BioNTech in the 4th quarter worth approximately $153,000. Finally, Rockefeller Capital Management L.P. grew its position in BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after purchasing an additional 1,423 shares during the period. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.